Motixafortide
- Evidence
- Approved drug evidence
- Class
- CXCR4 antagonist peptide
Motixafortide belongs to the CXCR4 antagonist peptide class. This library groups it under heart & blood. Its source category is FDA-approved.
At a glance
| Compound class | CXCR4 antagonist peptide |
|---|---|
| Associated brands | Aphexda |
| Body system | Heart & blood |
| Use or research focus | Stem cell mobilization in multiple myeloma |
| Regulatory status | FDA-approved (2023) |
| Source evidence rating | Approved drug evidence |
How does Motixafortide work?
Mobilizes hematopoietic stem cells.
The source catalog maps this mechanism to Blood / Hematologic. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
An approved medicine can still have contraindications, interactions, and serious adverse effects. The current prescribing label is the place to check product-specific warnings. A clinician should review your medical history and other medicines before treatment.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Motixafortide?
Motixafortide belongs to the CXCR4 antagonist peptide class. This library groups it under heart & blood. Its source category is FDA-approved. Its recorded use or research focus is: Stem cell mobilization in multiple myeloma.
Is Motixafortide FDA-approved?
The catalog records: FDA-approved (2023). Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.
Where can I read the research?
The Citations tab contains 2 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for heart & blood
Factual catalog fields and citation links are adapted from Superpower’s Motixafortide guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Motixafortide in the source dataset. Open a source to review its study design, population, limitations, and date.
View the original research guide